We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
+2.81%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$414M
AUM Growth
+$142M
Cap. Flow
+$137M
Cap. Flow %
33.08%
Top 10 Hldgs %
55.2%
Holding
74
New
15
Increased
11
Reduced
28
Closed
14

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$7.74M
2
UNH icon
UnitedHealth
UNH
+$7.22M
3
PFE icon
Pfizer
PFE
+$6.28M
4
THC icon
Tenet Healthcare
THC
+$3.92M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$3.28M

Sector Composition

Rank Sector Weight
1 Healthcare 58.08%
2 Energy 0.72%
3 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HUM icon
1
Humana
HUM
$43.7B
$8.62M 2.08%
32,500
+2,500
+8% +$634K
BSX icon
2
Boston Scientific
BSX
$69.5B
$8.6M 2.08%
200,000
-25,000
-11% -$962K
BDX icon
3
Becton Dickinson
BDX
$45.6B
$8.19M 1.98%
+33,313
New +$7.74M
UNH icon
4
UnitedHealth
UNH
$376B
$7.32M 1.77%
+30,000
New +$7.22M
DHR icon
5
Danaher
DHR
$137B
$7.15M 1.73%
56,400
-11,280
-17% -$1.34M
ELV icon
6
Elevance Health
ELV
$81.5B
$7.05M 1.71%
25,000
-2,500
-9% -$683K
BAX icon
7
Baxter International
BAX
$13.5B
$6.96M 1.68%
85,000
-20,000
-19% -$1.55M
ABT icon
8
Abbott
ABT
$183B
$6.73M 1.63%
80,000
-20,000
-20% -$1.57M
PFE icon
9
Pfizer
PFE
$143B
$6.5M 1.57%
+158,100
New +$6.28M
REGN icon
10
Regeneron Pharmaceuticals
REGN
$78.5B
$6.26M 1.51%
20,000
+7,000
+54% +$2.33M
LLY icon
11
Eli Lilly
LLY
$1.02T
$6.09M 1.47%
55,000
-15,000
-21% -$1.77M
LH icon
12
Labcorp
LH
$25B
$6.05M 1.46%
40,740
+11,640
+40% +$1.62M
MRK icon
13
Merck
MRK
$322B
$5.87M 1.42%
73,360
-26,200
-26% -$2.01M
EW icon
14
Edwards Lifesciences
EW
$49.6B
$5.73M 1.38%
93,000
+45,000
+94% +$2.72M
MOH icon
15
Molina Healthcare
MOH
$10.2B
$5.73M 1.38%
40,000
-15,000
-27% -$2.05M
WCG
16
DELISTED
Wellcare Health Plans, Inc.
WCG
$5.7M 1.38%
20,000
-15,000
-43% -$4.14M
CELG
17
DELISTED
Celgene Corp
CELG
$5.55M 1.34%
60,000
VRTX icon
18
Vertex Pharmaceuticals
VRTX
$121B
$5.5M 1.33%
30,000
BIO icon
19
Bio-Rad Laboratories Class A
BIO
$8.71B
$5.47M 1.32%
17,500
-2,500
-13% -$749K
HCA icon
20
HCA Healthcare
HCA
$87.2B
$5.41M 1.31%
40,000
-20,000
-33% -$2.53M
UHS icon
21
Universal Health Services
UHS
$10.2B
$5.22M 1.26%
40,000
-5,000
-11% -$629K
ELAN icon
22
Elanco Animal Health
ELAN
$13.2B
$5.07M 1.23%
150,000
-25,000
-14% -$812K
WMGI
23
DELISTED
Wright Medical Group Inc
WMGI
$4.77M 1.15%
160,000
TMO icon
24
Thermo Fisher Scientific
TMO
$213B
$4.41M 1.07%
15,000
-5,000
-25% -$1.38M
SNN icon
25
Smith & Nephew
SNN
$13.3B
$4.35M 1.05%
100,000
-10,000
-9% -$414K

Similar funds

Sivik Global Healthcare's Q2 2019 Portfolio in Review

As of Q2 2019, Sivik Global Healthcare held 74 positions worth $414M, up 52% from $271M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Sivik Global Healthcare deployed $137M of net new capital in Q2 2019, opening 15 new positions and adding to 11 existing holdings. Its largest new stake was Becton Dickinson: 33,313 shares worth $8.19M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 93% a quarter earlier, followed by Energy and Utilities.

On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $4.14M trimmed.

  • Sivik Global Healthcare's largest Q2 2019 buy was Becton Dickinson: 33,313 shares worth $8.19M.
  • Sivik Global Healthcare added most to Edwards Lifesciences in Q2 2019, an estimated $2.72M increase.
  • Sivik Global Healthcare's biggest Q2 2019 reduction was Wellcare Health Plans, Inc., cutting an estimated $4.14M.
  • Sivik Global Healthcare fully exited Novo Nordisk in Q2 2019, selling an estimated $7.06M.
  • Sivik Global Healthcare's ten largest holdings make up 55% of its $414M portfolio in Q2 2019.
  • Sivik Global Healthcare opened 15 new positions and closed 14 in Q2 2019.
  • Sivik Global Healthcare's portfolio value rose 52% quarter-over-quarter to $414M.

Based on Sivik Global Healthcare's 13F filing for Q2 2019, filed 14 Aug 2019.